Furthermore, to illustrate its ability to recover biologically meaningful results, we also applied the competitive peptide set test to a published proteomics dataset to compare the tumor proteomes of tamoxifen-sensitive and tamoxifen-resistant estrogen receptor (ER)-positive breast cancer patients (De Marchi et al. 2016). The gene discussed is ESR1; the disease is breast carcinoma.